Literature DB >> 15278103

Hepatic steatosis in obese Chinese children.

D F Y Chan1, A M Li, W C W Chu, M H M Chan, E M C Wong, E K H Liu, I H S Chan, J Yin, C W K Lam, T F Fok, E A S Nelson.   

Abstract

THE AIMS OF OUR STUDY WERE: (1) to determine the prevalence of asymptomatic hepatic steatosis and presumed nonalcoholic steatohepatitis, in our local population of obese Chinese children referred for medical assessment; and (2) to assess the correlation between severity of ultrasonographic hepatic steatosis and degree of obesity, insulin resistance and serum biochemical abnormalities.
DESIGN: Cross-sectional study.
METHODS: In total, 84 obese children, 25 girls and 59 boys with median age and body mass index (BMI) of 12.0 years (interquartile range (IR): 9.5-14.0) and 30.3 kg/m(2) (IR: 27.1-33.4), respectively, referred for medical assessment were studied. All subjects underwent physical examination, anthropometric and dual energy X-ray absorptiometry (DEXA) scan measurements and real-time ultrasonographic (US) examination of the liver. Fasting blood samples were collected for the measurement of liver function, hepatitis status, levels of serum glucose and insulin and lipid profile. Degree of fatty infiltration of the liver was graded according to ultrasonic appearance of liver echotexture, liver-diaphragm differentiation in echo amplitude, hepatic echo penetration and clarity of hepatic blood vessels.
RESULTS: All recruited subjects had no history of alcohol abuse and tests for Hepatitis B or C virus were negative. Thorough examination showed all of them to be in general good health without signs of chronic liver disease. Hepatic steatosis identified by defined ultrasonic appearances was diagnosed in 65 subjects (77%); 17 girls and 48 boys. The severity of fatty liver was positively related to anthropometric measurements including BMI, waist and hip circumference, subscapular skinfold thickness; insulin resistance markers [QUICKI and homeostasis model assessment (HOMA)], and hypertriglyceridaemia. Multvariate ordinal regression analysis showed that BMI and raised alanine aminotransferase (ALT) were positively associated with fatty liver. Combination of hepatic steatosis with raised ALT (presumptive NASH) was found in 19 subjects (24%). This group of patients had significantly higher waist hip ratio and conicity index compared to those with isolated hepatic steatosis. Boys with presumed NASH were also found to have significantly higher insulin resistance.
CONCLUSION: Nonalcoholic fatty liver disease (NAFLD) was common among our cohort of obese children referred for medical assessment. The prevalence of simple steatosis and presumed NASH was 77 and 24%, respectively. The severity of US steatosis was positively correlated with BMI, raised ALT, insulin resistance and hypertryglyceridaemia. Ultrasonography being noninvasive and readily available could be used for the monitoring of the progression of hepatic steatosis. Further longitudinal studies are required to determine the natural disease progression and the role of insulin resistance and other factors in the pathophysiology of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278103     DOI: 10.1038/sj.ijo.0802734

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  67 in total

1.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

2.  Overview of screening methods for fatty liver disease in children.

Authors:  Caroline Anitha Devadason; Ann O Scheimann
Journal:  World J Hepatol       Date:  2012-01-27

3.  Fatty liver disease in children: eat now pay later.

Authors:  Ruth M L De Bruyne; Emer Fitzpatrick; Anil Dhawan
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

4.  Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology.

Authors:  Yoshihisa Takahashi; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

5.  A Computer-Aided Diagnosis Scheme For Detection Of Fatty Liver In Vivo Based On Ultrasound Kurtosis Imaging.

Authors:  Hsiang-Yang Ma; Zhuhuang Zhou; Shuicai Wu; Yung-Liang Wan; Po-Hsiang Tsui
Journal:  J Med Syst       Date:  2015-11-12       Impact factor: 4.460

6.  Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease.

Authors:  P-F Chang; Y-C Lin; K Liu; S-J Yeh; Y-H Ni
Journal:  Int J Obes (Lond)       Date:  2015-04-03       Impact factor: 5.095

7.  The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy.

Authors:  Raquel M S Campos; Aline de Piano; Patrícia L da Silva; June Carnier; Priscila L Sanches; Flávia C Corgosinho; Deborah C L Masquio; Marise Lazaretti-Castro; Lila M Oyama; Cláudia M O Nascimento; Lian Tock; Marco Túlio de Mello; Sergio Tufik; Ana R Dâmaso
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

8.  Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference.

Authors:  Kunihiko Tominaga; Edward Fujimoto; Keiko Suzuki; Masayuki Hayashi; Masao Ichikawa; Yutaka Inaba
Journal:  Environ Health Prev Med       Date:  2009-01-31       Impact factor: 3.674

9.  Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits.

Authors:  Goro Tsuruta; Naoki Tanaka; Minoru Hongo; Michiharu Komatsu; Akira Horiuchi; Kaeko Hamamoto; Chieko Iguchi; Yoshiko Nakayama; Takeji Umemura; Tetsuya Ichijo; Akihiro Matsumoto; Kaname Yoshizawa; Toshifumi Aoyama; Eiji Tanaka
Journal:  J Gastroenterol       Date:  2010-01-19       Impact factor: 7.527

10.  Anthropometric and metabolic characteristics in children with clinically diagnosed nonalcoholic fatty liver disease.

Authors:  Diana R Mager; Simon Ling; Eve A Roberts
Journal:  Paediatr Child Health       Date:  2008-02       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.